Cyprus vs United States of America: Share of adolescent girls vaccinated against human papillomavirus
Cyprus
67.0%
in 2024
United States of America
65.0%
in 2024
Cyprus rank
36th
United States of America rank
38th
Share of adolescent girls vaccinated against human papillomavirus over time
- Cyprus
- United States of America
How they compare
Cyprus currently reports 67.0% against 65.0% in United States of America, a difference of 2.0%.
The two have swapped places 1 time across 7 shared years of data; in 2018 it was United States of America ahead.
Cyprus ranks 36th and United States of America ranks 38th of 74 countries.
United States of America has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cyprus | United States of America | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 56.5% | 58.5% | 2.0% | United States of America |
| 2020s | 65.2% | 66.2% | 1.0% | United States of America |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of adolescent girls vaccinated against human papillomavirus, Cyprus or United States of America?
- Cyprus, at 67.0% against 65.0% in United States of America as of 2024.
- What is the difference in share of adolescent girls vaccinated against human papillomavirus between Cyprus and United States of America?
- 2.0%, with Cyprus ahead.
- How many years of comparable data are there for Cyprus and United States of America?
- 7 years are reported by both, from 2018 to 2024.
- How do Cyprus and United States of America rank globally for share of adolescent girls vaccinated against human papillomavirus?
- Cyprus ranks 36th and United States of America ranks 38th of 74 countries.
- Where does this data come from?
- WHO & UNICEF (2025) – processed by Our World in Data, published as Share of adolescent girls vaccinated against human papillomavirus. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of fifteen-year-old girls who, between the ages of 9 and 14, received their last dose of the human papillomavirus vaccine.